The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in ...

The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press ...

Chennai: In a meaningful step towards transforming liver cancer care in India, Apollo Proton Cancer Centre (APCC), Chennai, ...

Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food ...

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...

Sirtex Medical’s SIR-Spheres Y-90 resin microspheres receive US FDA nod to treat unresectable hepatocellular carcinoma: Woburn, Massachusetts Tuesday, July 8, 2025, 17:00 Hrs [I ...

The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive ...

Sirtex Medical announced that the FDA has approved the company’s SIR-Spheres yttrium-90 (Y90) resin microspheres for the trea ...

Workers operate the extraction of Yttrium-90 glass microspheres irradiated in the "Hefu-1" unit at the Qinshan Nuclear Power Plant in Haiyan, East China's Zhejiang Province on June 14. Photo: Courtesy ...

AstraZeneca is conducting a Phase II clinical study titled Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres ...